References

I-149

1. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2014;64(18):1929-1949.
2. Grolez G, Moreau C, Sablonniere B, et al. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. *BMC Neurol.* 2015;15:74.
3. National Institute for Health and Care Excellence. Autism spectrum disorder in under 19s: Support and management. Coverage Guideline 170. 2013; updated June 2021.
4. Fulgenzi A, Ferrero ME. EDTA chelation therapy for the treatment of neurotoxicity. *International Journal of Molecular Sciences.* 2019;20(5):1019.
5. Adal A. Medscape. Heavy metal toxicity. 2018; http://emedicine.medscape.com/article/814960-overview. Accessed December 18, 2019.
6. Mathew RO, Schulman-Marcus J, Nichols EL, et al. Chelation Therapy as a Cardiovascular Therapeutic Strategy: The Rationale and the Data in Review. *Cardiovasc Drugs Ther.* 2017;31(5-6):619-625.
7. Nunez MT, & Chana-Cuevas P. New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases. 2018;11(4):109.
8. Ujueta F, Arenas IA, Escolar E, et al. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT). *J Diabetes Complications.* 2019;33(7):490-494.
9. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2017;135(12):e726-e779.